Navigation Links
DiagnoCure's GCC marker for the staging of colorectal cancer discussed at the Eastern Cooperative Oncology Group
Date:7/2/2008

QUEBEC CITY, July 2 /PRNewswire-FirstCall/ - DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced today that Dr. Timothy J. Holzer, Vice President, R&D and Production at DiagnoCure, and Dr. Scott Waldman, from Thomas Jefferson University, were speakers on June 29, 2008, in Boston, Massachusetts, in a session at the Eastern Cooperative Oncology Group (ECOG), one of the largest clinical cancer research organizations in the United States. Dr. Holzer and Dr. Waldman discussed with members of the GI (gastro-intestinal) committee about the importance of DiagnoCure's GCC mRNA molecular marker in the staging of colorectal cancer.

Dr. Holzer presented research data on "Molecular Detection of Colorectal Cancer Lymph Node Micrometastasis". His presentation featured a statistical review and discussion of the beneficial role of GCC in the staging of colorectal cancer. Dr. Waldman discussed his discovery and recently completed clinical studies about the significant staging role of GCC in colorectal cancer in a talk entitled "Molecular Approaches to Individualized Management of Cancer".

GCC is expressed only in intestinal mucosal cells, but not in extra-intestinal tissues. In addition, GCC is expressed in colorectal tumors, but not in other cancers outside the gastro-intestinal tract. Therefore, GCC may be useful clinically for the management of patients with colorectal cancer in providing more accurate information about lymph node metastasis to physicians and patients and influencing treatment decisions.

About Previstage(TM) GCC

Staging a patient with colorectal cancer is crucial because it determines the patient's course of treatment. Current standard of care requires that pathologists examine microscopically a thin slice of tissue from each of 12 or more lymph nodes harvested during the patient's surgery to see if cancer has spread beyond the intestine. Currently up to 25 - 30 percent of patients with no histopathologically-positive lymph nodes (stage I and II cancers) later return with recurrent disease, presumably through occult metastases that have escaped detection. Most of these patients do not receive additional treatment such as chemotherapy. Previstage(TM) GCC aims to provide clinicians with a significantly more sensitive tool for staging a patient with colorectal cancer.

Clinical data from a 5-year prospective clinical study supported the potential importance of the GCC test in improving the staging of colorectal cancer patients. This study was sponsored by the National Cancer Institute. The study has been completed and the Company's collaborators at Thomas Jefferson University will be presenting the results of the study at major medical conferences later this year.

About DiagnoCure

DiagnoCure (TSX: CUR) is a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services that increase clinician and patient confidence in making critical treatment decisions. DiagnoCure is currently preparing to launch the Previstage(TM) GCC Colorectal Cancer Staging Test, the first GCC-based molecular test for the management of colorectal cancer. In 2003, the Company entered into a strategic alliance with Gen-Probe (NASDAQ: GPRO) for the development and commercialization of a second-generation test for PCA3, DiagnoCure's proprietary molecular marker highly specific to prostate cancer. The test is now available through laboratories in the U.S. using PCA3 analyte specific reagents (ASR) from Gen-Probe, in Europe as the CE-marked PROGENSA(TM) PCA3 in vitro assay, and in Canada. In addition to its own research, the Company intends to acquire or in-license additional promising cancer biomarkers from both academic and commercial institutions. For more information, visit http://www.diagnocure.com.

Forward-looking statements

This release contains forward-looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. By their very nature, forward-looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. As a result, investors are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues are based on management expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward-looking statements contained herein.


'/>"/>
SOURCE DIAGNOCURE INC.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Photos: For the First Time Researchers Show Reversal of an Aging Marker in the Human Retina Correlated with Visual Improvement Using a Nutraceutical Matrix (Longevinex(R))
2. Elevated biomarkers predict risk for prostate cancer recurrence
3. Pancreatic Cancer Biomarkers Found
4. MultiVu Video Feed: Study in the New England Journal of Medicine Shows High Blood Pressure Drug Tekturna(R) Reduces Key Marker of Kidney Disease
5. Celebrex May Reduce Levels of Lung Cancer Biomarker
6. USC researchers identify genetic markers that predict efficacy of novel cancer drug
7. New prognostic markers for gastric cancer patients
8. Biomarkers Predict Heart Deaths
9. Doctors Discover Marker for Meconium Passage During Delivery
10. Biomarker Spots Which Lesions Likely to Progress to Prostate Cancer
11. Monoclonal antibody Hb3: A marker for colon cancer progression or as a therapeutic target?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... is supporting the upcoming 2016 Miss Arizona pageant as its official Medspa Sponsor. ... Scottsdale, Tempe, Mesa, and Chandler, Arizona. , Dr. Olson says the decision ...
(Date:6/24/2016)... AZ (PRWEB) , ... June 24, 2016 , ... SpiritQuest ... the heart of West Sedona, surrounded by famous vortex sites: Cathedral Rock, Airport Mesa, ... from partner properties – the Lodge at Sedona as well as the Sedona Rouge, ...
(Date:6/23/2016)... TX (PRWEB) , ... June 23, 2016 , ... The ... and business clients throughout Jasper County and the surrounding region, is initiating a charity ... charity drive will raise funds earmarked for a scholarship fund that will be presented ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
Breaking Medicine Technology: